ISSN 2398-2942      

Tigilanol tiglate

icanis

Synonym(s): Stelfonta


Introduction

Name

  • Tigilanol tiglate. 

Class of drug

  • Antineoplastic.

Description

Chemical name

  • (1aR,1bR,1cS,2aR,3S,3aS,6aS,6bR,7R,8R,8aS)-3,3a,6b-Trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-{[(2S)-2-methylbutanoyl]oxy}-4-oxo-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-1H-cyclopropa[5', 6']benzo[1',2':7,8]azuleno[5,6-b]oxiren-8-yl (2E)-2-methyl-2-butenoate.

Molecular formula

  • C30H42O10  

Molecular weight

  • 562.6

Physical properties

  • Clear colourless solution for injection. 

Storage requirements

  • Store in a refrigerator (2-8°C).
  • Do not freeze.
  • Protect from light.
  • The proposed shelf-life of 42 months when stored in a refrigerator (2-8°C). 

Uses

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Indications

  • Treatment of non-resectable, non-metastatic (WHO staging) subcutaneous mast cell tumors Skin: mastocytoma located at or distal to the elbow or the hock, and non-resectable, non-metastatic cutaneous mast cell tumors in dogs (must be less than or equal to 8 cm3 in volume and accessible to intratumoral injection). 

Administration

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Pharmacokinetics

Precautions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Further Reading

Publications

Refereed Papers

  • Recent references from PubMed and VetMedResource.
  • De Ridder T R, Campbell J E, Burke‐Schwarz C et al (2020) Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46). JVIM doi.org/10.1111/jvim.15806 PubMed.
  • De Ridder T, Ruppin M, Wheeless M, Williams S, Reddell P (2020) Use of the intratumoural anticancer drug tigilanol tiglate in two horses. Front Vet Sci 7,639 PubMed.
  • Miller J, Campbell J, Blum A et al (2019) Dose characterization of the investigational anticancer drug tigilanol tiglate (EBC‐46) in the local treatment of canine mast cell tumors. Front Vet Sci 6, 106 doi.org/10.3389/fvets.2019.00106 PubMed.
  • Panizza B J, de Souza P, Cooper A, Roohullah A, Karapetis C S, Lickliter J D (2019) Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine 50, 433-444 PubMed.
  • Boyle G M, D’Souza MM  A, Pierce C J, Adams R A, Cantor A S, Johns J P, Maslovskaya L, Gordon V A, Reddell P W & Parsons P G (2014) Intralesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PLoS ONE 9(10), e108887 PubMed.

Other sources of information

MEMBER BENEFIT

Can’t find what you’re looking for?

We have an ever growing content library on Vetlexicon so if you ever find we haven't covered something that you need please fill in the form below and let us know!